These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30723467)

  • 21. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy.
    Ma CK; Clancy L; Deo S; Blyth E; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2017 Jan; 19(1):107-118. PubMed ID: 27793552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
    Haines BB; Denslow A; Grzesik P; Lee JS; Farkaly T; Hewett J; Wambua D; Kong L; Behera P; Jacques J; Goshert C; Ball M; Colthart A; Finer MH; Hayes MW; Feau S; Kennedy EM; Lerner L; Quéva C
    Cancer Immunol Res; 2021 Mar; 9(3):291-308. PubMed ID: 33355229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
    Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
    Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
    Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
    Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unique Type I Interferon, Expansion/Survival Cytokines, and JAK/STAT Gene Signatures of Multifunctional Herpes Simplex Virus-Specific Effector Memory CD8
    Vahed H; Agrawal A; Srivastava R; Prakash S; Coulon PA; Roy S; BenMohamed L
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncotarget Strategies For Herpes Simplex Virus-1.
    Zhang L; Tatsuya T; Nishiyama Y
    Curr Gene Ther; 2016; 16(2):130-43. PubMed ID: 27029942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
    Todo T; Martuza RL; Rabkin SD; Johnson PA
    Proc Natl Acad Sci U S A; 2001 May; 98(11):6396-401. PubMed ID: 11353831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
    Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
    J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells.
    Barrio MM; Abes R; Colombo M; Pizzurro G; Boix C; Roberti MP; Gélizé E; Rodriguez-Zubieta M; Mordoh J; Teillaud JL
    PLoS One; 2012; 7(7):e40311. PubMed ID: 22768350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macrophage polarization contributes to the efficacy of an oncolytic HSV-1 targeting human uveal melanoma in a murine xenograft model.
    Liu S; Zhang J; Fang S; Zhang Q; Zhu G; Tian Y; Zhao M; Liu F
    Exp Eye Res; 2021 Jan; 202():108285. PubMed ID: 33039456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of a cellular vaccination approach consisting of crawling dendritic cells (CDCs) transduced with HSV-1-Deltapac vectors.
    Nuñez R; Fraefel C; Suter M; Nuñez-Liman A; Liou HC; Ackerman M
    Immunol Res; 2004; 30(1):105-24. PubMed ID: 15258314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Us3 kinase encoded by herpes simplex virus 1 mediates downregulation of cell surface major histocompatibility complex class I and evasion of CD8+ T cells.
    Imai T; Koyanagi N; Ogawa R; Shindo K; Suenaga T; Sato A; Arii J; Kato A; Kiyono H; Arase H; Kawaguchi Y
    PLoS One; 2013; 8(8):e72050. PubMed ID: 23951282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
    Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
    Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
    Kaufman HL; Kim DW; DeRaffele G; Mitcham J; Coffin RS; Kim-Schulze S
    Ann Surg Oncol; 2010 Mar; 17(3):718-30. PubMed ID: 19915919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effective Priming of Herpes Simplex Virus-Specific CD8
    Whitney PG; Makhlouf C; MacLeod B; Ma JZ; Gressier E; Greyer M; Hochheiser K; Bachem A; Zaid A; Voehringer D; Heath WR; Wagle MV; Parish I; Russell TA; Smith SA; Tscharke DC; Gebhardt T; Bedoui S
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
    Hao M; Huang C; Xia N
    Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Herpes simplex virus-specific human cytotoxic T-cell colonies expressing either gamma delta or alpha beta T-cell receptor: role of accessory molecules on HLA-unrestricted killing of virus-infected targets.
    Maccario R; Comoli P; Percivalle E; Montagna D; Locatelli F; Gerna G
    Immunology; 1995 May; 85(1):49-56. PubMed ID: 7635521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.